AI Article Synopsis
- The study analyzed the long-term outcomes of 44 patients who experienced cerebral venous sinus thrombosis after receiving the ChAdOx1 nCoV-19 COVID-19 vaccine.
- Assessments using the Extended Glasgow Outcome Scale showed that 29.6% of patients had a good recovery, while 50% experienced varying degrees of disability.
- Tragically, 31.8% of the patients resulted in fatal outcomes, underscoring the serious risks associated with this rare condition following vaccination.
Article Abstract
We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3-6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255460 | PMC |
| http://dx.doi.org/10.1038/s41541-022-00491-z | DOI Listing |
Publication Analysis
Top Keywords
cerebral venous
8
venous sinus
8
sinus thrombosis
8
patients
6
long-term outcome
4
outcome patients
4
patients vaccine-induced
4
vaccine-induced immune
4
immune thrombotic
4
thrombotic thrombocytopenia
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!